超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國NobleGen Biosciences  
一家位于馬塞諸塞州的新創公司卓越基因（Noblegen）正在研發簡化版納米孔基因組測序技術（nanopore genome-sequencing technology）——這項技術使得平常需要復雜儀器來完成的高速廉價DNA測序充滿希望。卓越基因公司去年春天建立，它稱自己的技術能夠直接快速地識讀DNA序列，使得將測序技術帶入臨床檢驗科進行癌癥和其他疾病的診斷在經濟上變得切實可行。

卓越基因公司的首席執行官弗蘭克·菲絲特（Frank Feist）說，公司的目標是以每秒50個堿基的速度進行測序。公司不會透露其目前樣機的細節，但稱此技術會擴增至400x400的納米孔陣列，每小時測序量超過5千億堿基（gigabases）——或者15分鐘約30個人類基因組。


NobleGen Biosciences is building a novel DNA sequencing instrument to enable cost effective personalized medicine, based on highly differentiated IP exclusively licensed from Harvard University and Boston University.

NobleGen’s ‘Optipore’ DNA sequencing platform will be the first to take advantage of a highly effective nanopore-based DNA separation method, which incorporates high-speed optical detection. Low instrument cost and sub micro-liter sample volumes are possible through the use of custom solid-state nanochips, imaged by a simple optical configuration that employs state of the art sCMOS technology, and an off-line chemical DNA conversion process. The Optipore solution enables high accuracy and throughput providing a cost effective solution for whole genome sequencing. Noblegen’s goal is to offer the best cost and performance of any single molecule instrument truly transforming medical prevention, diagnosis and therapy.

Prof. Meller invented the Optipore optical nanopore sequencing technology at Harvard University between 2001 and 2005 and has been developing a prototype sequencer at Boston University since 2006. Prof. Meller has won multiple NIH/NHGRI and NSF awards for Optipore development ($8.3M total). First to publish results obtained from a laboratory prototype demonstrating very accurate, single molecule, multiplex reads of all 4 nucleotide bases from a nanopore array in 5/2010, Prof. Meller has been awarded a $4.2M/ 4 year extension grant in the latest (9/2010) round of NHGRI funding. NobleGen was incorporated in 2/2010 and exclusively licensed the Optipore technology from Harvard University and Boston University in 8/2010. NobleGen has raised seed funding including a highly competitive $200K Launch Award from Boston University.

NobleGen’s headquarters and biochemistry lab are located in Boston, MA.